Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322883 | 0.88 | POLB (0.51) | SMN1; SMN2HPGDRAB9AALDH1A1KMT2A | |
| SCHEMBL5191103 | 0.81 | RAB9A (0.51) | SMN1; SMN2HPGDRAB9AALDH1A1MEN1 | |
| SCHEMBL24323854 | 0.79 | NPC1 (0.60) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL24322763 | 0.76 | KMT2A (0.44) | SMN1; SMN2HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL22221105 | 0.76 | HTR2C (0.68) | SMN1; SMN2HPGDRAB9AALDH1A1HTR2C | |
| SCHEMBL24653102 | 0.74 | HTR2C (0.70) | SMN1; SMN2HPGDRAB9AALDH1A1NPC1 | |
| SCHEMBL28747806 | 0.74 | FDPS (0.45) | SMN1; SMN2NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL24323552 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2NPSR1RAB9AALDH1A1MEN1 | |
| SCHEMBL24322789 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2NPSR1RAB9AALDH1A1MEN1 | |
| SCHEMBL24322395 | 0.72 | FDPS (0.44) | SMN1; SMN2NPSR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | SMN1; SMN2 4226/4885NPSR1 4254/4885HPGD 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.